This report resistance % | INICC 2007–2012 resistance % | NHSN 2009–2010 resistance, % | |
---|---|---|---|
Pathogen, antimicrobial | (CLABSI) | (CLABSI) | (CLABSI) |
Staphylococcus aureus | |||
Oxacillin | 92.7% | 61.2% | 54.6% |
Enterococcus faecalis | |||
Vancomycin | 5.0% | 12.2% | 9.5% |
Pseudomonas aeruginosa | |||
Ciprofloxacine | 35.3% | 37.5% | 30.5% |
Piperacillin or piperacillin-tazobactam | 27.6% | 33.5% | 17.4% |
Amikacin | 18.9% | 42.8% | 10.0% |
Imipenem or meropenem | 37.1% | 42.4% | 26.1% |
Klebsiella pneumoniae | |||
Ceftriaxone or ceftazidime | 55.7% | 71.2% | 28.8% |
Imipenem or meropenem | 6.3% | 19.6% | 12.8% |
Acinetobacter baumanii | |||
Imipenem or meropenem | 56.1% | 66.3% | 62.6% |
Escherichia Coli | |||
Ceftriaxone or ceftazidime | 55.2% | 65.9% | 19.0% |
Imipenem or meropenem | 4.4% | 8.5% | 1.9% |
Ciprofloxacine | 66.2% | 69.3% | 41.8% |